Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31264174 | 0.84 | AURKA (0.43) | ALDH1A1HPGDMAPTKMT2ALMNA | |
| SCHEMBL16806498 | 0.84 | L3MBTL1 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3004070 | 0.82 | KDM4E (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16003797 | 0.81 | AHR (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16781951 | 0.81 | KDM4E (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31132611 | 0.80 | GAA (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31133164 | 0.80 | ALDH1A1 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31133176 | 0.79 | CA12 (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3348874 | 0.73 | KDM4E (0.44) | HTTKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL31456625 | 0.73 | AHR (0.38) | HTTKDM4EALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024038132-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| EP-4292662-A2 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-3423435-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
| CN-106957317-B | Novel pyrazole derivatives | 持田制药株式会社 | 2019-12-31 | — | — | CN | disclosed |
| US-8980889-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8980889-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8980889-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20140378448-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378447-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378448-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378448-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378447-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378447-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| WO-2014133046-A1 | NOVEL PYRAZOLE DERIVATIVE | 持田製薬株式会社 (JP) | 2014-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | CA12 4778/4885CA1 4679/4885CA2 4689/4885 |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | CA12 3510/4885CA1 1612/4885CA2 342/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | CA12 4778/4885CA1 4679/4885CA2 4689/4885 |
| US-20140378447-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | CA12 4442/4885CA1 3079/4885CA2 2605/4885 |
| US-20140378448-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | CA12 4442/4885CA1 3079/4885CA2 2605/4885 |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | CA12 4778/4885CA1 4679/4885CA2 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.